Spero Therapeutics, Inc.
Income Statement
| Line Item | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.2M | $9.3M | $73.5M | $25.5M | $2.7M | $2.1M | $47.4M | $2.0M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $23.7M | $17.3M | $16.6M | $16.4M | $9.5M | $9.0M | $15.1M | $7.4M |
| SG&A Expense | $5.5M | $5.9M | $6.4M | $5.7M | $6.1M | $7.3M | $6.5M | $6.6M |
| Operating Income | $-19.1M | $-14.0M | $50.5M | $-1.9M | $-12.9M | $-14.2M | $25.9M | $-11.8M |
| Operating Margin | -186.9% | -150.9% | 68.7% | -7.6% | -474.6% | -687.6% | 54.6% | -589.9% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | $2.2M | — | — | — | $0 |
| Net Income | $-17.9M | $-12.7M | $51.2M | $-3.2M | $-11.9M | $-13.3M | $26.8M | $-11.7M |
| Net Margin | -175.2% | -136.7% | 69.6% | -12.6% | -438.1% | -642.8% | 56.5% | -583.3% |
| EPS (Basic) | $-0.33 | $-0.24 | $0.97 | $-0.06 | $-0.23 | $-0.25 | $0.98 | $-0.33 |
| EPS (Diluted) | $-0.33 | $-0.24 | $0.97 | $-0.06 | $-0.23 | $-0.25 | $0.98 | $-0.33 |
| Shares Outstanding (Basic) | 54.0M | 53.5M | 52.7M | 52.7M | 52.6M | 52.5M | 37.6M | 35.9M |
| Shares Outstanding (Diluted) | 54.0M | 53.5M | 53.0M | 52.7M | 52.6M | 52.5M | 37.6M | 35.9M |
| Dividends Per Share | — | — | — | — | — | — | — | — |